Extended N-terminal somatostatin
AssigneeThe Salk Institute for Biological Studies
InventorsRoger C. L. Guillemin, Nicholas C. Ling, Fred S. Esch, Peter Bohlen, Paul E. Brazeau, Jr.
Life of this patent
Estimating the term…
Abstract
28-member residue and 25-member residue peptides have been synthesized containing the tetradecapeptide somatostatin that are more potent than somatostatin. Somatostatin-28 has the formula: ##STR1## The three N-terminal amino acid residues are absent in somatostatin-25. Somatostatin-28 or somatostatin-25 or a pharmaceutically acceptable addition salt thereof, dispersed in a pharmaceutically acceptable liquid or solid carrier, can be administered to mammals in the same manner as somatostatin.
Claims6
A pharmaceutical composition comprising synthetic somatostatin-28, synthetic somatostatin-25 or the nontoxic addition salts thereof, and a pharmaceutically acceptable liquid or solid carrier therefor.
A method of inhibiting the release of growth hormone in a mammal, which comprises administering to said mammal an effective amount for inhibiting growth hormone release of a material selected from the class consisting of somatostatin-28, somatostatin-25 and the nontoxic acid addition salts thereof.
##STR8## wherein R.sub.1 is Ser or des R.sub.1 ;
- R.sub.2 is Ala or des R.sub.2 ;
- and R.sub.3 is Asn or des R.sub.3 ;
- having a purity of at least about 95%, or the linear version thereof where the disulfide bridge is replaced by hydrogen.
A pharmaceutical composition comprising [D-Trp.sup.22 ]-somatostatin-28 or a nontoxic addition salt thereof and a pharmaceutically acceptable liquid or solid carrier therefor.
##STR9## having a purity of at least about 95%, or the linear version thereof where the disulfide bridge is replaced by hydrogen.
Dependencies are inferred from the claim text.